BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barnett ANR, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N. The use of eculizumab in renal transplantation. Clin Transplant 2013;27:E216-29. [DOI: 10.1111/ctr.12102] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Durigutto P, Sblattero D, Biffi S, De Maso L, Garrovo C, Baj G, Colombo F, Fischetti F, Di Naro AF, Tedesco F, Macor P. Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. Front Immunol 2017;8:1093. [PMID: 28932227 DOI: 10.3389/fimmu.2017.01093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
2 Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061-1073. [PMID: 25651368 DOI: 10.1038/ki.2014.423] [Cited by in Crossref: 234] [Cited by in F6Publishing: 194] [Article Influence: 33.4] [Reference Citation Analysis]
3 Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, Singer AL, Carter-Monroe N, Nazarian SM, Segev DL. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14:459-465. [PMID: 24400968 DOI: 10.1111/ajt.12540] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 12.5] [Reference Citation Analysis]
4 Cohen D, Rijnink EC, Nabuurs RJA, Steup-beekman GM, Versluis MJ, Emmer BJ, Zandbergen M, van Buchem MA, Allaart CF, Wolterbeek R, Bruijn JA, van Duinen SG, Huizinga TWJ, Bajema IM. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology 2016;56:77-86. [DOI: 10.1093/rheumatology/kew341] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
5 Matsuda Y, Watanabe T, Li XK. Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells. Front Immunol 2021;12:682334. [PMID: 34276669 DOI: 10.3389/fimmu.2021.682334] [Reference Citation Analysis]
6 Danobeitia JS, Djamali A, Fernandez LA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair 2014;7:16. [PMID: 25383094 DOI: 10.1186/1755-1536-7-16] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
7 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
8 Howard MC, Nauser CL, Farrar CA, Sacks SH. Complement in ischaemia-reperfusion injury and transplantation. Semin Immunopathol 2021;43:789-97. [PMID: 34757496 DOI: 10.1007/s00281-021-00896-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 La Hoz RM, Baddley JW. Infectious Complications of Immune Modulatory Agents. Curr Infect Dis Rep 2013;15:465-71. [DOI: 10.1007/s11908-013-0365-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
10 James A, Mannon RB. The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? Curr Transplant Rep 2015;2:113-21. [PMID: 26236578 DOI: 10.1007/s40472-015-0052-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
11 Zaza G, Tomei P, Granata S, Boschiero L, Lupo A. Monoclonal antibody therapy and renal transplantation: focus on adverse effects. Toxins (Basel) 2014;6:869-91. [PMID: 24590384 DOI: 10.3390/toxins6030869] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, Bruijn JA, Bajema IM, Cohen D. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. J Am Soc Nephrol. 2015;26:2239-2247. [PMID: 25573909 DOI: 10.1681/asn.2014050429] [Cited by in Crossref: 62] [Cited by in F6Publishing: 25] [Article Influence: 8.9] [Reference Citation Analysis]
13 Danobeitia JS, Djamali A, Fernandez LA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair 2014;7:16. [PMID: 25383094 DOI: 10.1186/1755-1536-7-16] [Cited by in Crossref: 57] [Cited by in F6Publishing: 1] [Article Influence: 7.1] [Reference Citation Analysis]
14 Parlakpinar H, Gunata M. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs. Immunopharmacol Immunotoxicol 2021;43:651-65. [PMID: 34415233 DOI: 10.1080/08923973.2021.1966033] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Chua S, Wong G, Lim WH. The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome. BMJ Case Rep. 2014;2014:pii: bcr2013202875. [PMID: 24671321 DOI: 10.1136/bcr-2013-202875] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Khan MA, Alanazi F, Ahmed HA, Vater A, Assiri AM, Broering DC. C5a Blockade Increases Regulatory T Cell Numbers and Protects Against Microvascular Loss and Epithelial Damage in Mouse Airway Allografts. Front Immunol 2018;9:1010. [PMID: 29881374 DOI: 10.3389/fimmu.2018.01010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Wohlfahrtova M, Viklicky O. Recent trials in immunosuppression and their consequences for current therapy. Curr Opin Organ Transplant 2014;19:387-94. [PMID: 24905020 DOI: 10.1097/MOT.0000000000000093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
18 de Andrade LGM, Contti MM, Nga HS, Bravin AM, Takase HM, Viero RM, da Silva TN, Chagas KN, Palma LMP. Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS One 2017;12:e0188155. [PMID: 29136640 DOI: 10.1371/journal.pone.0188155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
19 West-Thielke P, Progar K, Campara M, Jasiak N, Gallon L, Tang I, Spaggiari M, Tzvetanov I, Benedetti E. Eculizumab for Prevention of Antibody-Mediated Rejection in Blood Group-Incompatible Renal Transplantation. Transplant Proc. 2018;50:66-69. [PMID: 29407333 DOI: 10.1016/j.transproceed.2017.12.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort: Eculizumab treatment of aHUS in Australia. Intern Med J 2015;45:1054-65. [DOI: 10.1111/imj.12864] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
21 Asgari E, Farrar CA, Sacks SH. Control of innate immunological mechanisms as a route to drug minimization. Curr Opin Organ Transplant 2014;19:342-7. [PMID: 24905023 DOI: 10.1097/MOT.0000000000000094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Khan MA, Shamma T. Complement factor and T-cell interactions during alloimmune inflammation in transplantation. J Leukoc Biol 2019;105:681-94. [PMID: 30536904 DOI: 10.1002/JLB.5RU0718-288R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Farrar CA, Sacks SH. Mechanisms of rejection: role of complement. Current Opinion in Organ Transplantation 2014;19:8-13. [DOI: 10.1097/mot.0000000000000037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
24 Thomas KA, Valenzuela NM, Gjertson D, Mulder A, Fishbein MC, Parry GC, Panicker S, Reed EF. An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. Am J Transplant 2015;15:2037-49. [PMID: 25904443 DOI: 10.1111/ajt.13273] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
25 Pankewycz O, Soliman K, Laftavi MR. The increasing clinical importance of alloantibodies in kidney transplantation. Immunological Investigations 2014;43:775-89. [DOI: 10.3109/08820139.2014.910016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Castañeda-Sanabria J, Hajage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol 2016;72:737-46. [PMID: 26915814 DOI: 10.1007/s00228-016-2027-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
27 Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017;187:304-15. [PMID: 27784126 DOI: 10.1111/cei.12890] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
28 Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost 2014;12:1437-9. [DOI: 10.1111/jth.12639] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
29 Sharif-Paghaleh E, Yap ML, Meader LL, Chuamsaamarkkee K, Kampmeier F, Badar A, Smith RA, Sacks S, Mullen GE. Noninvasive Imaging of Activated Complement in Ischemia-Reperfusion Injury Post-Cardiac Transplant. Am J Transplant. 2015;15:2483-2490. [PMID: 25906673 DOI: 10.1111/ajt.13299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
30 Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013;122:2003-7. [PMID: 23814021 DOI: 10.1182/blood-2013-05-501445] [Cited by in Crossref: 165] [Cited by in F6Publishing: 139] [Article Influence: 18.3] [Reference Citation Analysis]
31 Pouliquen E, Koenig A, Chen CC, Sicard A, Rabeyrin M, Morelon E, Dubois V, Thaunat O. Recent advances in renal transplantation: antibody-mediated rejection takes center stage. F1000Prime Rep 2015;7:51. [PMID: 26097724 DOI: 10.12703/P7-51] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
32 Roversi P, Ryffel B, Togbe D, Maillet I, Teixeira M, Ahmat N, Paesen GC, Lissina O, Boland W, Ploss K, Caesar JJ, Leonhartsberger S, Lea SM, Nunn MA. Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury. J Biol Chem 2013;288:18789-802. [PMID: 23625922 DOI: 10.1074/jbc.M112.420331] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
33 Danobeitia JS, Ziemelis M, Ma X, Zitur LJ, Zens T, Chlebeck PJ, Van Amersfoort ES, Fernandez LA. Complement inhibition attenuates acute kidney injury after ischemia-reperfusion and limits progression to renal fibrosis in mice. PLoS One 2017;12:e0183701. [PMID: 28832655 DOI: 10.1371/journal.pone.0183701] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
34 Ochando J, Ordikhani F, Boros P, Jordan S. The innate immune response to allotransplants: mechanisms and therapeutic potentials. Cell Mol Immunol 2019;16:350-6. [PMID: 30804476 DOI: 10.1038/s41423-019-0216-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]